BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Songbirds swap colorful plumage genes across species lines among their evolutionary neighbors - 2Judge sets $60K bond for Florida congresswoman accused of stealing $5M in COVID-19 funds
- 3Major railway disruptions persist as Germany braces for more snow
- 4Israel and Lebanon's Hezbollah continue to trade attacks
- 5Russian authorities threaten WhatsApp with total ban
- Figure out How to Get the Best Open Record Rewards
- The Most Well known Online Entertainment Forces to be reckoned with of 2023
- There’s ‘super flu,’ COVID, RSV. Is it going around in SoCal?
- Witness the elegance of the cosmic butterfly in a remarkable telescope photo
- Polish law aimed at lowering petrol prices takes effect
- Ten Awesome Authentic Realities That Will Leave You Interested
- CDC studies show value of nationwide wastewater disease surveillance, as potential funding cut looms
- Heartfelt Objections to Visit with Your Adored One
- Pick Your Favored kind of soup
